Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

Table 1 Patients baseline characteristics and 5-fluorouracil exposure

Total (n = 81)	Capecitabine	S-1	P value
	(n = 41)	(n = 40)
Age
Median (Range)	61 (39-77)	63 (41-78)	0.175
Gender, n (%)
Male	24 (59)	27 (67)	0.404
Female	17 (41)	13 (33)
ECOG performance status, n (%)
0-1	30 (73)	29 (72)	0.946
2	11 (27)	11 (28)
Disease status at diagnosis, n (%)
Resectable	15 (36)	26 (65)
Locally advanced	4 (10)	2 (5)
Metastatic	19 (46)	12 (30)
Missing data	3 (7)	0
Overall disease classification, n (%)
Initially unresectable	23 (56)	14 (35)	0.057
Locally advanced	4 (9)	2 (5)
Distant metastasi	19 (46)	12 (30)
Recurrent	18 (44)	26 (65)
Prior treatment, n (%)
Surgery	18 (44)	26 (65)	0.057
Radiotherapy	17 (41)	11 (28)	0.186
Adjuvant chemotherapy	14 (34)	19 (48)	0.221
Number of previous regimens received, n (%)
1	40 (98)	36 (90)	0.201
> 2	1 (2)	4 (10)
Subsequent chemotherapy after oral chemotherapy, n (%)	12 (29)	17 (43)	0.214
Prior gemcitabine-based regimen, n (%)
Gemcitabine	8 (20)	9 (22)
Gemcitabine/erlotinib	31 (76)	7 (18)
Gemcitabine/cisplatin	2 (5)	0
Gemcitabine/nab-paclitaxel	0	24 (60)
5-Fluorouracil exposure, n (%)	13 (31)	19 (50)	0.146

ECOG: Eastern Cooperative Oncology Group.